PDGF-D Inhibitors
PDGF-D inhibitors constitute a diverse group of compounds that directly or indirectly modulate the signaling pathways activated by PDGF-D, primarily focusing on the PDGFR tyrosine kinase activity. Imatinib, Sunitinib, Dasatinib, AG1295, Crenolanib, Nintedanib, GW2580, CP-673451, Masitinib, Bosutinib, and CUDC-101 collectively exemplify the class of PDGF-D inhibitors. Imatinib, a tyrosine kinase inhibitor, directly targets PDGFR, suppressing PDGF-D signaling and subsequently inhibiting downstream pathways involved in cell growth and survival. Sunitinib, another multi-targeted kinase inhibitor, includes PDGFR among its targets, interfering with PDGF-D-mediated signaling pathways associated with angiogenesis and tumor growth.
Dasatinib, AG1295, Crenolanib, GW2580, CP-673451, Masitinib, Bosutinib, and CUDC-101 are specific inhibitors of PDGFR tyrosine kinase activity. These compounds directly modulate PDGF-D signaling by targeting the kinase activity of PDGFR, resulting in the suppression of downstream cellular responses linked to PDGF-D, such as cell proliferation and migration. Nintedanib, a triple kinase inhibitor, targets PDGFR along with other kinases, providing a broad impact on PDGF-D signaling. Erlotinib, primarily an EGFR inhibitor, indirectly influences PDGF-D signaling by affecting common downstream pathways shared with EGFR. CP-673451, with potent inhibition of PDGFR, directly suppresses PDGF-D signaling and its associated cellular responses. Collectively, PDGF-D inhibitors showcase a targeted approach toward interfering with PDGF-D signaling pathways, providing a foundation for understanding the molecular mechanisms involved.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets PDGF receptor (PDGFR) among other kinases. By inhibiting PDGFR, Imatinib directly suppresses PDGF-D signaling, preventing downstream activation of intracellular pathways involved in cell growth and survival. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that includes PDGFR among its targets. By inhibiting PDGFR, Sunitinib interferes with PDGF-D-mediated signaling pathways, impacting cellular processes related to angiogenesis and tumor growth. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that targets multiple kinases, including PDGFR. By inhibiting PDGFR, Dasatinib directly modulates PDGF-D signaling, leading to the suppression of downstream pathways involved in cell proliferation and migration. | ||||||
Tyrphostin AG 1295 | 71897-07-9 | sc-3558 sc-3558A | 5 mg 25 mg | $102.00 $265.00 | 12 | |
AG1295 is a specific inhibitor of PDGFR tyrosine kinase activity. By directly targeting PDGFR, AG1295 disrupts PDGF-D signaling and inhibits downstream cellular responses associated with PDGF-D, such as cell proliferation and migration. | ||||||
Crenolanib | 670220-88-9 | sc-364470 sc-364470A | 5 mg 10 mg | $600.00 $1000.00 | ||
Crenolanib is a tyrosine kinase inhibitor with activity against PDGFR. By inhibiting PDGFR, Crenolanib directly interferes with PDGF-D signaling, leading to the modulation of downstream pathways involved in cellular processes such as proliferation and survival. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $180.00 $315.00 | 2 | |
Nintedanib (BIBF1120) is a triple kinase inhibitor that targets PDGFR, among other kinases. By inhibiting PDGFR, Nintedanib directly affects PDGF-D signaling, leading to the suppression of downstream pathways associated with fibrosis and angiogenesis. | ||||||
cFMS Receptor Tyrosine Kinase Inhibitor | 870483-87-7 | sc-203877 sc-203877A | 1 mg 5 mg | $31.00 $53.00 | ||
cFMS Receptor Tyrosine Kinase Inhibitor (GW2580) is a selective inhibitor of PDGFR tyrosine kinase activity. By directly targeting PDGFR, GW2580 inhibits PDGF-D signaling, influencing downstream cellular responses linked to PDGF-D, including cell migration and proliferation. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor, and since PDGFR shares downstream signaling pathways with EGFR, Erlotinib indirectly modulates PDGF-D signaling by affecting common pathways. It disrupts the cascades involved in cell proliferation, survival, and migration, impacting cellular responses associated with PDGF-D. | ||||||
Masitinib | 790299-79-5 | sc-211777 | 10 mg | $180.00 | ||
Masitinib is a tyrosine kinase inhibitor with selectivity for PDGFR among other kinases. By inhibiting PDGFR, Masitinib directly modulates PDGF-D signaling, impacting downstream pathways involved in processes like angiogenesis and fibrosis. | ||||||